Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ROCKET AF Yields Positive Results For Xarelto, But A Few Chinks In The Armor

Executive Summary

Bayer/J&J’s factor Xa inhibitor Xarelto (rivaroxaban) met its endpoints in the head-to-head ROCKET AF study against warfarin, but on some major bleeding outcomes measures it actually did worse than warfarin, and the effects of the widely used generic appear to have been sub-par in the 14,000-patient study.
Advertisement

Related Content

Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
The Power Of Pradaxa: Physicians Weigh In
The Power Of Pradaxa: Physicians Weigh In
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa

Topics

Advertisement
UsernamePublicRestriction

Register

PS052863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel